Overview

A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The study is designed to assess the efficacy and safety of patient-initiated therapy with famciclovir 1500 mg o.d. or 750 mg b.i.d. for one day treatment in adult men and women with recurrent herpes labialis

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

2-Aminopurine
Famciclovir